Blog

  • Content Europe prepares to connect buyers and sellers around formats, factual and drama in Lisbon in April 2026 | News

    Content Europe prepares to connect buyers and sellers around formats, factual and drama in Lisbon in April 2026 | News

    Earlybird registration is set to close at the end of October for C21’s new three-day format-focused market, conference and screenings event, which is set to take place in Lisbon between April 21 and 23, 2026.

    The event is designed as a sales and acquisitions market, connecting buyers and sellers around formats, factual and drama. It will be supported by a two-track conference programme: the Future Formats Forum and The Content Acquisitions Summit.

    The Marriott Lisbon will host Content Europe

    Both these tracks will be focused on uncovering content trends, buyer priorities, and sales and coproduction opportunities across channels and platforms worldwide. They will mine data from C21’s ongoing Content Strategies premium report strand.

    C21’s editor-in-chief & managing director David Jenkinson said: “The focus on formats and factual at Content Europe has been welcomed by the business and we are set to announce some significant speakers and initiatives around the event in the coming weeks. It’s clear the demand for a sales and acquisitions market in the spring is strong following the closure of MipTV, but what is also clear is that these genres are the ones currently defining global business.

    “We have already taken additional space at The Marriott in Lisbon to accommodate high demand for the event and will be making a number of further announcements shortly.”

    C21 has signed a deal with Amsterdam-based LineUp Industries to become an event partner on Content Europe, with founders Julian Curtis and Ed Louwerse joining the advisory board.

    Curtis (left) said: “The demise of MipTV left a big gap in the formats calendar. Our sector will benefit hugely from a dedicated industry gathering and we’re looking forward to working with C21 in delivering an event that gives a voice to all parts of the business – indies to studios, big or small. We aim to make this not just a market but a fun celebration of what we do and the value we deliver.”

    Content Europe has also announced that Formats Biz founder Chiara Duranti has joined the advisory board. “Chiara is a champion of global formats and her insights will provide a valuable contribution to the event,” Jenkinson added.

    Duranti said: “I’m truly honoured to join the advisory board of Content Europe. As founder of FormatBiz, I believe it’s crucial to have a space that both tracks global trends in scripted and unscripted formats and supports real exchange between buyers and distributors. This new spring market is a timely and strategic response to the industry’s evolving needs.”

    Further information will be announced shortly.

    The building blocks of Content Europe are:

    Continue Reading

  • Dancing dust devils on Mars trace raging winds

    Dancing dust devils on Mars trace raging winds

    The Colour and Stereo Surface Imaging System (CaSSIS) on board ESA’s ExoMars Trace Gas Orbiter (TGO) captured this dust devil tracking across the Martian surface on December 3, 2021. Studying dust devils on Mars helps scientists trace the red…

    Continue Reading

  • NeurologyLive® Brain Games: October 12, 2025 | NeurologyLive

    NeurologyLive® Brain Games: October 12, 2025 | NeurologyLive

    Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields…

    Continue Reading

  • Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology

    Subcutaneous Pembrolizumab Shows Possibility of Providing Effective and Convenient Treatment in Oncology

    Subcutaneously administered systemic therapies are expected to reduce administration times, minimizing the time an individual treatment chair or room is needed while simultaneously giving patients the freedom to choose how to spend more of their time outside the clinic, according to J. Thaddeus Beck, MD, FACP.

    The most recent regulatory approval of subcutaneous treatment was announced on September 19, 2025, when the FDA approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous injection for use in adult and pediatric patients aged 12 years and older in all solid tumor indications approved for the intravenous (IV) formulation of pembrolizumab (Keytruda).1,2

    The agent was tested in the phase 3 Study MK-3475A-D77 (NCT05722015) in patients with untreated, metastatic non–small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 genomic tumor aberrations. Patients were randomly assigned to receive subcutaneous pembrolizumab (n = 251) or IV pembrolizumab administered every 6 weeks with platinum doublet chemotherapy.

    The results showed that the predefined acceptance margin was met for the pharmacokinetic end points with the lower boundary, 96% CI for cycle 1 area under the curve 0 to 6 weeks, and 94% CI for cycle 3 Ctrough, of the geometric mean ratios above the prespecified threshold of 0.8 for comparability. Descriptive analyses of efficacy also indicated that the confirmed objective response rate was 45% (95% CI, 39%-52%) in the subcutaneous arm vs 42% (95% CI, 33%-51%) in the IV arm. Progression-free survival and overall survival outcomes were also similar between arms.

    “I think [this approval] is the wave of the future. [I expect that] more of these monoclonal [antibodies] will be given subcutaneously,” J. Thaddeus Beck, MD, FACP, medical oncologist at Highlands Oncology in Rogers, Arkansas, said in an interview with OncLive®.

    In the interview, Beck discussed the regulatory agency’s approval of subcutaneous pembrolizumab, its significance for patients and providers, and considerations that should be made before the agent is introduced into clinical practices.

    OncLive: What makes this approval of subcutaneous pembrolizumab meaningful?

    Beck: The approval of the subcutaneous form of pembrolizumab gives us another option that we can use to tailor treatments for patients’ individual situations. The main benefit is the ease and simplicity of administration [since it allows for a] shortened administration time. It’s a 2.4 mL or 0.5 teaspoon size injection that can be given in seconds instead of [over 30 minutes].

    We’ve had very good feedback from patients who are on the trial [about] how it really changed the way they thought about treatment. They liked the fact that it was shorter and quicker, so that they could be in and out. They could have more time to do what they wanted to do before and after their treatment, [providing] much more of a pleasant experience for them.

    What will be the immediate effect of the approval?

    The patients like it better. It will save chair time, so treatment chairs or rooms will not be occupied as long. You can cut the infusion time down. If it’s being given with another IV chemotherapy, you can drop the last infusion, given that it is subcutaneous, and the patients will have a better experience.

    What is important to note about the design of the pivotal trial?

    The trial was designed with two arms that compared sequential treatment. The first arm was IV therapy for [X] cycles, followed by subcutaneous therapy. The second arm was subcutaneous therapy, followed by IV therapy. Then patients were allowed to assess how they felt with the treatment and choose which one they’d like to continue with. Most patients chose the subcutaneous version.

    There were no unique adverse effects or safety signals. Other than the administration difference, [the subcutaneous formulation] seemed to act in the same form and fashion [as the IV formulation].

    What is your advice to those looking to integrate the subcutaneous formulation into their practice?

    People have to get partially undressed [to receive the therapy], so you’ll need a private area to [allow for that]. We’re in the process of building a new facility, and we’re taking this change into account. We’re creating a whole separate fast track area where patients can [experience] the faster workflow and have more privacy, so they can take advantage of this program.

    Continue Reading

  • Prince Edward receives ‘delightful’ nod with link to prominent royal figure

    Prince Edward receives ‘delightful’ nod with link to prominent royal figure



    Prince Edward receives ‘delightful’ nod with link to prominent royal figure

    The Duke…

    Continue Reading

  • ‘Useful feedback can come in very ugly packaging’: Oscar-winning actress Julia Roberts opens up on handling harsh career criticism creatively

    ‘Useful feedback can come in very ugly packaging’: Oscar-winning actress Julia Roberts opens up on handling harsh career criticism creatively

    Even an Academy Award on your shelf cannot shield you from criticism — Julia Roberts knows that better than most. The Hollywood icon, celebrated for her roles in Pretty Woman and Erin Brockovich, recently opened up about how early-career…

    Continue Reading

  • IsDB issues another successful Green Sukuk under enhanced Sustainable Finance Framework | News

    IsDB issues another successful Green Sukuk under enhanced Sustainable Finance Framework | News

    8 October 2025 – The Islamic Development Bank (IsDB, the Bank) raised EUR 500 million through its latest Green benchmark Sukuk issuance under its enhanced 2025 Sustainable Finance Framework (the Framework).

    The Bank, rated Aaa/AAA/AAA by S&P, Moody’s and Fitch (all with Stable Outlook) priced the 5-year Trust Certificates under its US$25 billion Trust Certificate Issuance Programme.

    The Joint Lead Managers (JLMs) for this issuance were Barclays, BNP Paribas, Commerzbank, Crédit Agricole CIB, HSBC Bank plc, ING and Nomura.

    The transaction is the Bank’s first EUR benchmark issuance this year. This followed its two other successful public USD benchmark transactions that raised a total of ~USD 3.5 billion from the global capital markets earlier this year. IsDB has now completed its 2025 funding program.

    The latest Green Sukuk issuance, the Bank’s second overall, represents an important milestone for IsDB in the EUR markets, positioning the Bank as a future frequent EUR issuer.

    The issuance witnessed a record-breaking orderbook– both in terms of both volume (5 times over subscription) and number of investors – reflecting the Bank’s very active investor outreach with EUR investors over the recent months and the robust market demand for AAA-rated paper in a challenging market environment. The Bank’s active investor engagement over the months culminated in a large increment of new investors participating in this issuance.

    The proceeds of the EUR 500 million Green Sukuk issuance will be deployed to finance and re-finance (in whole or in part) eligible projects with environmental benefits under the ‘Green Project categories’ as defined in the Framework.

    This is IsDB’s first Green Sukuk under the newly‑launched Framework that was published in July 2025 and supersedes the 2019 Framework. The enhanced Framework aligns with the latest editions of the ICMA Principles and Guidelines, including the 2025 Green Bond Principles, the 2025 Social Bond Principles and the 2021 Sustainability Bond Guidelines.

    The Framework introduces more stringent eligibility criteria for green project categories and detailed criteria for social project categories. The Bank also added two new eligible categories in the Framework, namely (a) Climate Change Adaptation and (b) Food Security and Sustainable Food Systems, reinforcing their role in its overall operations strategy and reflecting the increasing project approvals in these sectors in recent years.

    The enhanced Framework was reviewed independently by S&P Global, which then published a strong Second Party Opinion (SPO) whereby most of the project categories were assigned Medium Green and Dark Green shading. S&P also noted that there are no weaknesses in the Framework and that it is fully aligned with the ICMA Principles.

    Execution Timeline

    IsDB formally announced to the market, on Wednesday 24 September 2025, a fixed income mandate for the JLMs to arrange a series of virtual calls and physical meetings in UK, France and The Netherlands, with a potential new 5-year Green EUR Sukuk issuance to follow, subject to market conditions.

    Throughout the week of 29September, the Bank met with a diverse range of investors, particularly focusing on ESG dedicated accounts. The Bank was also building upon the investor outreach that it had undertaken across Northern and Southern Europe in early September.

    Despite a volatile backdrop, market conditions were supportive for IsDB to announce a EUR 500mn Will Not Grow (WNG) 5-year Green Sukuk transaction on Tuesday, 7 October. After gathering positive interest, the Bank officially opened the orderbook the next morning, on Wednesday, 8 October, with a guidance of EUR SOFR Mid Swap (MS) plus 47 basis (bps) area.

    Investor demand quickly exceeded EUR 1.5 billion (bn), enabling the Bank to set the final spread at EUR SOFR MS plus 44 bps, i.e. three bps tighter from guidance. This translates to a profit rate of 2.793% for investors, payable on an annual basis and priced at par.

    The momentum continued even with the tighter pricing and final orderbooks closed in excess of EUR 2.6bn (incl. EUR 225mn JLM), resulting in IsDB’s most oversubscribed trade ever as well as its largest EUR book on record.

    The final distribution was very well diversified across investor types: Central Banks / Official Institutions / Sovereign Wealth Fund (42%); Asset Managers / Fund Managers (30%); Insurance and Pension Funds (22%); and Banks / Treasury (6%).

    From a geographical point of view, Europe turned out with the largest share (53%), followed by MENA (27%), Asia (13%) and the UK (7%).

    Dr. Zamir Iqbal, the Vice President (Finance) and CFO of IsDB, said: “The work on the Bank’s enhanced Sustainable Finance Framework reflects the Bank’s commitment to further scale up sustainable development in our Member Countries. The latest AAA-rated EUR Green Sukuk is a landmark achievement that showcases the Bank’s impact and capabilities. The strongest credential for the Bank is very strong interest of investors – we are grateful for their endorsement and confidence in the Bank’s mission and its sustainable finance framework.”

    Mr. Mohammed Sharaf, the IsDB Treasurer and Mr. Zakky Bantan, the Manager of the Capital Markets Division added, “The most significant takeaway from this issuance is the influx of new investors. Extensive investor outreach, together with the robust Sustainable Finance Framework, made this possible. We highly appreciate all the support from investors. We look forward to build upon this success for future issuances when we return to the EUR markets next year.”

    Jamie Stirling, the Global Head of SSA Debt Capital Markets at BNP Paribas concluded: “An impressive issuance by IsDB that underscores the growing appetite of European investors for high-quality AAA exposure in the region. Partnering with IsDB and the other lead managers, we assembled a broad, diversified investor base – many of them first-time Sukuk participants – demonstrating the confidence placed on IsDB Green Sukuk paper. Congratulations to all the team, a very well-deserved result.”

    IsDB is a AAA-rated supranational and multilateral development financial institution with 57 Member Countries (MCs) and a mandate of delivering social and economic development with a focus on sustainability in its Member countries and Muslim communities worldwide. The Bank’s operations span across four continents, touching the lives of nearly 1 in 5 of the global population. Its mission is to equip people to drive their own economic and social progress at scale, putting the infrastructure in place and enabling them to fulfil their potential. The Bank’s targeted efforts across multiple continents foster an environment where the primary focus is on human development and well-being.

    Continue Reading

  • A Fundamental Mismatch Between Assets and Liabilities in the Banking Sector

    A Fundamental Mismatch Between Assets and Liabilities in the Banking Sector

    Yield levels on deposits in many fintech companies are dramatically higher than yield levels on deposits in the banking sector, see chart below. It is a fundamental imprudence in banking to finance long-horizon assets with short-term liabilities.

    Sources: Revolut, Varo Bank, Adelfi, Pibank, Sofi, FitnessBank, AlumniFi, LendingClub, Current, Wealthfront, FDIC, Haver Analytics, Apollo Chief Economist

    Download high-res chart


    This presentation may not be distributed, transmitted or otherwise communicated to others in whole or in part without the express consent of Apollo Global Management, Inc. (together with its subsidiaries, “Apollo”).  

    Apollo makes no representation or warranty, expressed or implied, with respect to the accuracy, reasonableness, or completeness of any of the statements made during this presentation, including, but not limited to, statements obtained from third parties. Opinions, estimates and projections constitute the current judgment of the speaker as of the date indicated. They do not necessarily reflect the views and opinions of Apollo and are subject to change at any time without notice. Apollo does not have any responsibility to update this presentation to account for such changes. There can be no assurance that any trends discussed during this presentation will continue.   

    Statements made throughout this presentation are not intended to provide, and should not be relied upon for, accounting, legal or tax advice and do not constitute an investment recommendation or investment advice. Investors should make an independent investigation of the information discussed during this presentation, including consulting their tax, legal, accounting or other advisors about such information. Apollo does not act for you and is not responsible for providing you with the protections afforded to its clients. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any security, product or service, including interest in any investment product or fund or account managed or advised by Apollo. 

    Certain statements made throughout this presentation may be “forward-looking” in nature. Due to various risks and uncertainties, actual events or results may differ materially from those reflected or contemplated in such forward-looking information. As such, undue reliance should not be placed on such statements. Forward-looking statements may be identified by the use of terminology including, but not limited to, “may”, “will”, “should”, “expect”, “anticipate”, “target”, “project”, “estimate”, “intend”, “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology.


    Continue Reading

  • Trace-Positive Sputum Identifies High Tuberculosis Risk

    Trace-Positive Sputum Identifies High Tuberculosis Risk

    A LONGITUDINAL study conducted in Kampala, Uganda, has revealed that individuals with trace-positive sputum (PWTS) on Xpert Ultra testing face a substantial risk of developing active tuberculosis over 2 years.  

    Community Screening Reveals…

    Continue Reading

  • Most anticipated originals you can’t miss

    Most anticipated originals you can’t miss



    Netflix line-up for November 2025: Most anticipated originals you can’t miss

    November 2025…

    Continue Reading